RAS-mutated
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC (NCT05970302) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-07-07 |
Track RAS-mutated automatically
Every clearance here is in the API, with alerts when new ones post.